380 related articles for article (PubMed ID: 29338113)
21. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension.
Li W; Gong M; Yu Q; Liu R; Chen K; Lv W; Yao F; Xu Z; Xu Y; Song W; Jiang Y
J Clin Hypertens (Greenwich); 2022 Apr; 24(4):449-456. PubMed ID: 35253964
[TBL] [Abstract][Full Text] [Related]
22. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
23. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension.
Hsiao HL; Langenickel TH; Petruck J; Kode K; Ayalasomayajula S; Schuehly U; Greeley M; Pal P; Zhou W; Prescott MF; Sunkara G; Rajman I
Clin Pharmacol Ther; 2018 Mar; 103(3):468-476. PubMed ID: 28599060
[TBL] [Abstract][Full Text] [Related]
25. Comparison of sacubitril/valsartan with olmesartan for hypertension: A meta-analysis of randomized controlled trials.
Sun Y; Yang H
Medicine (Baltimore); 2024 Apr; 103(14):e37501. PubMed ID: 38579097
[TBL] [Abstract][Full Text] [Related]
26. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.
Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
Clin Ther; 2010 Jul; 32(7):1252-69. PubMed ID: 20678674
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
Sica D; White WB; Weber MA; Bakris GL; Perez A; Cao C; Handley A; Kupfer S
J Clin Hypertens (Greenwich); 2011 Jul; 13(7):467-72. PubMed ID: 21762358
[TBL] [Abstract][Full Text] [Related]
28. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
29. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
Chrysant SG; Melino M; Karki S; Lee J; Heyrman R
Clin Ther; 2008 Apr; 30(4):587-604. PubMed ID: 18498909
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension.
Iwashima Y; Fukushima H; Horio T; Rai T; Ishimitsu T
J Clin Hypertens (Greenwich); 2023 Mar; 25(3):304-308. PubMed ID: 36722379
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.
Polina I; Domondon M; Fox R; Sudarikova AV; Troncoso M; Vasileva VY; Kashyrina Y; Gooz MB; Schibalski RS; DeLeon-Pennell KY; Fitzgibbon WR; Ilatovskaya DV
Am J Physiol Renal Physiol; 2020 Jul; 319(1):F63-F75. PubMed ID: 32463726
[TBL] [Abstract][Full Text] [Related]
32. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Brunner HR; Arakawa K
Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials.
Wu HX; Liu KK; Li BN; Liu S; Jin JC
Ann Palliat Med; 2022 May; 11(5):1811-1825. PubMed ID: 35672897
[TBL] [Abstract][Full Text] [Related]
34. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring.
Destro M; Scabrosetti R; Vanasia A; Mugellini A
Adv Ther; 2005; 22(1):32-43. PubMed ID: 15943220
[TBL] [Abstract][Full Text] [Related]
36. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
Malacco E; Omboni S; Mallion JM; Volpe M;
High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666
[TBL] [Abstract][Full Text] [Related]
37. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
Omboni S; Malacco E; Mallion JM; Volpe M
Drugs Aging; 2012 Dec; 29(12):981-92. PubMed ID: 23179896
[TBL] [Abstract][Full Text] [Related]
38. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
40. Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
Zemmrich C; Lüders S; Gansz A; Sturm CD; Fimmers R; Nadal J; Schmieder RE; Schrader J; Bramlage P
J Clin Hypertens (Greenwich); 2013 Nov; 15(11):815-9. PubMed ID: 24102831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
